Subtle Medical appoints Tanenbaum as executive medical director
- Subtle Medical appoints Lawrence N. Tanenbaum as Executive Medical Director and Medical Advisory Board Chair
- Dr. Tanenbaum serves as an advisor since 2019 and previously led technology strategy at RadNet
- The role focuses on guiding clinical strategy for AI solutions across MRI, PET, and CT platforms
- Subtle Medical currently has 11 FDA-cleared products and over 1,500 systems live globally
*this image is generated using AI for illustrative purposes only.
Subtle Medical appointed Lawrence N. Tanenbaum, MD, FACR, as Executive Medical Director and Chair of its Medical Advisory Board on Aug. 20, 2026. The expansion of his longstanding advisory role aims to accelerate the company's next generation of AI-powered medical imaging solutions.
Dr. Tanenbaum joins the leadership team after serving as an advisor since 2019. He previously led imaging technology strategy at RadNet and held academic roles at the Icahn School of Medicine at Mount Sinai. His career spans nearly 40 years in clinical radiology and innovation.
Strategic Role Expansion
The appointment marks a natural evolution of Dr. Tanenbaum's relationship with Subtle Medical. As Executive Medical Director, he will guide clinical strategy, product development, and evidence generation. He will work closely with Co-Founder and Chief Science Officer Dr. Enhao Gong to activate the company's network of key opinion leaders.
Ohad Arazi, CEO of Subtle Medical, stated that Dr. Tanenbaum's deep understanding of clinical realities and emerging technology will be invaluable. The company seeks to broaden its AI imaging platform across MRI, PET, and CT while scaling adoption among imaging providers.
Clinical Leadership Background
Dr. Tanenbaum brings extensive experience in translating imaging technologies into real-world practice. At RadNet, he helped deploy SubtleMR across hundreds of scanners, bringing accelerated, high-quality MRI into routine clinical use. He is a Fellow of the American College of Radiology and has authored more than 100 scholarly publications.
What the Numbers Show
Subtle Medical operates a significant installed base with 11 FDA-cleared products and over 1,500 systems live worldwide. The appointment of a high-profile clinical leader like Dr. Tanenbaum signals a strategic shift toward leveraging this existing infrastructure to drive deeper clinical validation and adoption across major imaging networks and academic centers.
About Subtle Medical
Subtle Medical provides AI-powered medical imaging solutions designed to improve image quality, workflow efficiency, and patient experience. Its deep-learning technologies work across imaging equipment and vendors, helping healthcare organizations maximize existing infrastructure performance.
How might Dr. Tanenbaum's leadership accelerate Subtle Medical's expansion into PET and CT imaging beyond its current MRI dominance?
What specific clinical evidence or regulatory milestones are expected to result from the new focus on evidence generation under Dr. Tanenbaum's direction?
Could this appointment signal an increased push for partnerships with major academic medical centers to validate AI imaging workflows?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
